What was done
This entry summarises the published human evidence for BPC-157, a synthetic fifteen-amino-acid peptide derived from a protein in human gastric juice, drawing on a 2025 literature and patent review and the public trial registry. [1][2]
What was found
The animal literature is extensive, largely from a single group at the University of Zagreb, and reports effects on tendon, muscle, gut and vascular repair. The human record is thin: a Phase I safety study registered in 2015 (NCT02637284) never posted results; the remaining human reports are small, uncontrolled pilots and a retrospective chart review of knee-pain patients. A randomised, placebo-controlled Phase 2 trial in acute grade II hamstring strain (NCT07437547) was registered in February 2026 and has no results yet. [1][2][3][4]
Limits
Absence of trials is not evidence of harm or of benefit; it is absence of evidence. Preclinical findings translate to humans at low rates, and animal doses do not map directly to people. [1][4]
Funding
The 2025 review is an academic publication; the Phase 2 trial is sponsored by Hudson Biotech according to the registry. [1][3]
SOURCES
- Józwiak M. et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. 2025. PMC11859134. Peer-reviewed. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859134/
- ClinicalTrials.gov. NCT02637284. Phase I, healthy volunteers. Registered 2015; no results posted. Registry record. https://clinicaltrials.gov/study/NCT02637284
- ClinicalTrials.gov. NCT07437547. Randomized, double-blind, placebo-controlled Phase 2 trial of BPC 157 for acute grade II hamstring strain. Registered Feb 2026. Registry record. https://clinicaltrials.gov/study/NCT07437547
- Irvine Health. BPC-157 in 2026: updated evidence and first human safety data. Apr 2026. Secondary summary. https://irvine.health/blogs/bpc157-update/
CHANGELOG · 5 Oct 2026 FIRST PUBLISHED · CORRECTIONS ARE ADDED HERE, NEVER HIDDEN